1. Psychiatrists are experts when it comes to missing boats. Will prevention be the next one?

   • Celso Arango

   Editorial 05 November 2019 Pages: 869 - 870

2. Relationship between duration of untreated prodromal symptoms and symptomatic and functional recovery

   • TianHong Zhang
   • LiHua Xu
   • JiJun Wang

   Original Paper 25 June 2018 Pages: 871 - 877

   

3. Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia

   • G. Fond
   • M. Faugere
   • C. Lançon

   Original Paper 04 August 2018 Pages: 879 - 886

4. Executive dysfunctions differentially predict amotivation in first-episode schizophrenia-spectrum disorder: a prospective 1-year follow-up study

   • Wing Chung Chang
   • Jasmine Tsz Ting Liu
   • Eric Yu Hai Chen

   Original Paper 22 June 2018 Pages: 887 - 896

5. Neural correlates of binocular depth inversion illusion in antipsychotic-naïve first-episode schizophrenia patients

   • Cathrin Rohleder
   • Dagmar Koethe
   • Dusan Hirjak

   Original Paper 19 March 2018 Pages: 897 - 910

   

6. The cognitive, affective motivational and clinical longitudinal determinants of apathy in schizophrenia

   • Stéphane Raffard
   • Catherine Bortolon
   • Delphine Capdevielle

   Original Paper 08 June 2018 Pages: 911 - 920

   

7. Antisaccade and prosaccade eye movements in individuals clinically at risk for psychosis: comparison with first-episode schizophrenia and prediction of conversion

   • Luca Kleineidam
   • Ingo Frommann
   • Ulrich Ettinger

   Original Paper 11 January 2019 Pages: 921 - 930

   

8. Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapine

   • Daniela Mier
   • Frederike Schirmbeck
   • Mathias Zink

   Original Paper Open access 11 December 2018 Pages: 931 - 940

   

9. Specificity proteins 1 and 4 in peripheral blood mononuclear cells in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial

   • Èlia Vila
   • Elena Huerta-Ramos
   • Belén Ramos

   Original Paper 30 August 2018 Pages: 941 - 948

   

10. Neurobiology of the major psychoses: a translational perspective on brain structure and function—the FOR2107 consortium

    • Tilo Kircher
    • Markus Wöhr
    • Udo Dannlowski

    Original Paper 28 September 2018 Pages: 949 - 962

    

11. Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer’s disease patients

    • Jessyka Maria de França Bram
    • Leda Leme Talib
    • Orestes Vicente Forlenza

    Original Paper 29 May 2018 Pages: 963 - 972

    

12. Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and early Alzheimer’s disease from bioptic olfactory mucosa

    • Hannah Pellkofer
    • Friedrich Ihler
    • Anja Schneider

    Original Paper 12 November 2018 Pages: 973 - 984

    

13. Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort

    • G. Fond
    • O. Godin
    • the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group

    Short Communication 28 May 2018 Pages: 985 - 992

    

14. Correction to: Cingulate abnormalities in bipolar disorder relate to gender and outcome: a region-based morphometry study

    • Giuseppe Delvecchio
    • Valentina Ciappolino
    • Paolo Brambilla

    Correction 15 June 2018 Pages: 993 - 993

15. Correction to: How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review

    • Eva Hoch
    • Dominik Niemann
    • Oliver Pogarell

    Correction Open access 05 April 2019 Pages: 995 - 995

16. Correction to: New trends in cannabis potency in USA and Europe during the last decade (2008–2017)

    • Suman Chandra
    • Mohamed M. Radwan
    • Mahmoud A. ElSohly

    Correction 23 May 2019 Pages: 997 - 997